Universitaetsklinikum Ulm AöR
- Address
- lock Available on a paid plan
Eye Diseases Research at Universitaetsklinikum Ulm AöR
The Klinik für Augenheilkunde in Ulm is conducting clinical research focused on eye diseases, especially conditions that affect vision and retinal health. These studies are aimed at improving treatment options and testing better ways to manage sight-threatening disorders.
- Research on exudative age-related macular degeneration and macular edema due to central retinal vein occlusion
- Evaluation of new and combined approaches to improve retinal disease treatment effectiveness
- Studies exploring whether care can be made more durable and less dependent on repeated interventions
These trials mainly address retinal and vascular eye conditions, with a focus on preserving vision, reducing disease burden, and refining treatment strategies for patients at the Universitaetsklinikum Ulm AöR.
Neoplasms and Breast Cancer Studies
Another major research area at this site involves neoplasms, with a strong emphasis on breast cancer. The studies include several forms of early and advanced disease, and they are designed to test new therapies, compare treatment strategies, and improve long-term cancer control.
- Research in triple-negative breast cancer and advanced HER2-negative, hormone receptor-positive breast cancer
- Studies in ER-positive/HER2-negative early breast cancer and related recurrence-risk settings
- Trials evaluating endocrine-based treatment approaches and newer targeted options for better disease control
Overall, the cancer portfolio at this hospital is centered on improving outcomes for patients with breast neoplasms, including efforts to delay recurrence, strengthen treatment response, and support more personalized care.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 12 therapeutic areas and 15 of 160 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 155 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 41 by active trials.
- 1GPOH gGmbH5active
lock +40 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1GPOH gGmbH5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Universitaetsklinikum Ulm AöR
lock Showing 1 of 68 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A 24-Month, Multi-Centre, Open Label Phase IV Post Authorisation Efficacy Study to Evaluate the Efficacy, Safety and Immunogenicity of Daily Subcutaneous Metreleptin Treatment in Patients with Partial Lipodystrophy | Chiesi Farmaceutici S.p.A. | Phase III | Recruiting | Dec 2023 | — |
IMP list
lock Showing 1 of 160 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Cyclophosphamide | 8 | Unknown | 2020-07-20 | 2025-12-24 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.